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CASE PRESENTATION
A 53-year-old Caucasian lady was evaluated in our
center as a potential kidney donor. She volunteered to
donate a kidney to her brother with whom she shared a
6/6-antigen match. The exact etiology of her brother’s
end-stage renal disease (ESRD) could not be determined.
On evaluation she was noted to be in good health and a
review of systems was unremarkable. Family history was
significant for functional pituitary tumor leading to
acromegaly and diabetes in her father and renal cell
carcinoma in her uncle. Physical examination revealed
that she was overweight with a body mass index of
31.2 kg/m2. Her blood pressure was 120/68 mm Hg, her
heart rate was 79 beats per minute and she was afebrile.
The remainder of the systemic examination was
unremarkable.
A transplant donor workup was completed (Table 1).
The pertinent abnormality was persistent microscopic
hematuria with two out of three urine analyses positive
for trace to 1þ blood in dipstick and 1–4 red cells on
microscopy. These urinalyses were performed on three
separate occasions at least 1 month apart. Urine cultures
were negative throughout. Gynecological examination,
which included a papanicolaou (PAP) smear, was
unremarkable.
The differential diagnosis for the microhematuria was
discussed with the patient. The patient was determined to
be considered as a candidate for kidney donation and
requested that we proceed to a percutaneous renal biopsy
in order to definitively identify the cause of hematuria.
The renal biopsy findings are shown in Figure 1a–c.
The core comprised of eight glomeruli. Light microscopy
showed glomeruli with normal cellularity, well-preserved
tubules and interstitium with no fibrosis or active
inflammation. The glomerular basement membranes
(GBMs) revealed no apparent abnormalities (Figure 1a).
Electron microscopy revealed thin GBMs with mean
thickness of 242 nm that was consistent with thin
basement membrane disease using the criteria by
Tiebosch et al.1 (Figure 1b). The mesangium was mildly
expanded by small irregular electron-dense deposits in
the matrix. Immunofluorescence was significant for
diffuse, fine-granular deposition of immunoglobulin (Ig)A
(lambda stronger than kappa) in the mesangial areas
(Figure 1c). A pathologic diagnosis of thin basement
membrane disease and Haas class I IgA nephropathy
(IgAN) was made.
CLINICAL DIAGNOSIS
Thin basement membrane abnormality and IgAN
in an otherwise healthy patient evaluated for kidney
donation.
FOLLOW-UP
The patient was counseled that kidney donation would not
be possible. Follow-up in the Chronic Kidney Disease
clinic was recommended. She was started on an
angiotensin-converting enzyme inhibitor (Lisinopril
5 mg/day) and fish oil (12 g each day). At her most recent
visit to the clinic, she was asymptomatic. She indicated
that she was taking her Lisinopril regularly but her
adherence to fish-oil therapy was at best sporadic. Her
renal function was stable (serum creatinine of 0.9 mg/dl
and negligible albuminuria).
DISCUSSION
The growing disparity between the supply and demand for
transplantable organs has added a tremendous strain on an
already overburdened, rapidly expanding transplant waiting
list. Consequently, significant number of ESRD patients die
owing to longer waiting time. While the supply of deceased
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donor kidneys has almost plateaued in most western
countries, live kidney donation is the only currently available
alternative to improve transplantation rate. Living kidney
donation has already surpassed deceased donor kidney
transplantations in some countries and is rapidly expanding
in the remaining countries globally. The prospective donor
pool is growing as the life expectancy of the population is
increasing. There is a growing pool of relatively healthy but
aged individuals to draw from for kidneys. These individuals
represent a population of ‘marginal donors’ – individuals at
Table 1 | Transplant donor workup
Urine dipstick pH 5.0, SG 1.014, trace blood, no protein
Urine microscopy 3–5 RBCs, 1–3 WBCs, no casts, no dysmorphic RBCs, and trace bacteria
Complete blood count Hb 15 g/dl, WBC 9.11 K/ml, platelets 359 K/ml
Renal function test BUN 16 mg/dl, creatinine 0.8 mg/dl
Glucose 76 mg/dl
HIV and Hepatitis screen Negative
24 h Urine collection GFR 121 cc/min, no microalbuminuria
Cystourethroscopy and bladder washings Negative for lower urinary tract source of bleeding
CT and MRI scans of the urinary tract Small benign cyst in the upper pole of left kidney, otherwise normal
BUN, blood urea nitrogen; CT, computed tomography; GFR, glomerular filtration rate; Hb, hemoglobin; HIV, human immunodeficiency virus; MRI, magnetic resonance
imaging; RBCs, red blood cells; SG, specific gravity; WBCs, white blood cells.
a b
c
Figure 1 | Renal histopathology. (a) Light microscopy of the kidney cortex: The glomerulus, one arteriole, and the surrounding tubules show a
normal appearance. There are no inflammatory lesion seen, and the mesangium appears delicate, without significant expansion of the matrix
or hypercellularity (toluidine blue semi-thin epoxy section). (b) Electron micrograph of the glomerular capillary wall: the endothelium and the
foot processes of the visceral epithelial cells are well preserved. The lamina densa of the GBM is attenuated and thin. (c) Immunofluorescence
microscopy image reveals discrete, fine-granular staining for IgA in the mesangial areas; the reactivity for lambda light chains was slightly
stronger than that for kappa light chains. All other Igs and complement components were negative.
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higher risk of cardiovascular disease, the presence of
prehypertension or treated mild hypertension, obesity, the
metabolic syndromes, and the presence of asymptomatic
urinary abnormalities such as hematuria or microscopic
hematuria. Whether these urinary abnormalities herald the
later development of kidney disease remains unclear.
However, in the past because of a higher perceived long-
term risk, a significant proportion of these candidates would
have been denied the option of donating a kidney. On the
other hand, some experts have argued that if the risk to the
potential donor is only minimally increased, these potential
and yet relatively marginal donors be considered as viable
candidates and should be accorded the right to determine for
themselves whether to take the risk of donating a kidney. In
these situations, input from an ethics committee may be
helpful. In this paper, we discuss the diagnostic workup,
differential diagnosis, and implications of accepting these
patients for kidney donation in the context of a case that
presents with asymptomatic urinary abnormalities.
Isolated, persistent microscopic hematuria
Microscopic hematuria noted in previously asymptomatic,
otherwise healthy potential kidney donors is an increasingly
common finding in the workup of kidney donors. Persistent
hematuria is defined as three or more red blood cells per
high-power field on microscopic evaluation of urinary
sediment from two of three properly collected urinalysis
specimens.2 Koushik et al.3 observed that in the University of
Minnesota kidney donor-screening program, the incidence
was 2.7% among 512 consecutive donor evaluations.
WORKUP FOR MICROSCOPIC HEMATURIA
A minimum of two urine dipstick tests should be performed
on separate occasions during the course of the donor
assessment to exclude the possibility of intermittent micro-
scopic hematuria. The dipstick is the most reliable and
sensitive test (can detect even 1–2 red blood cells per high-
power field). Hence, a negative dipstick can reliably exclude
clinically significant hematuria.4 An examination of fresh-
centrifuged urine sediment for the presence of red cells and
cellular casts could point to the possibility of glomerular
bleeding. Routine mid stream urine specimens without
centrifugation will not reliably exclude hematuria. A
persistent hematuric state as detected by two or more
urinalyses over at least 1-month period, in the absence of
obvious factors such as menstruation or infection requires
full investigation. An algorithm for the workup of hematuria
in a kidney donor is shown in Table 2.
Isolated hematuria could result from glomerular bleeding
or secondary to extraglomerular causes like nephrolithiasis,
urothelial malignancy, and prostatic disease (Table 3).
Glomerular bleeding, in most cases, is due to one or more
of three disorders: thin basement membrane nephropathy
(TBMN, also called benign familial hematuria), IgAN, and
Alport’s syndrome (AS, also known as hereditary nephritis)
or a carrier state. A careful history and renal functional
assessment of the prospective donor, as well as repeated
urinalysis on all family members can suggest the type of
inheritance and the most likely genetic basis of the disease.
The clinical evaluation should include any previous history of
kidney stones, symptoms of pain, dysuria or prostatism, and
a family history of hematuria. Hypercalciuria and hyper-
uricosuria are shown to be important causes of isolated
hematuria both in children and adults. Both disorders are
often associated with a positive family history and could be
screened by analysis of a 24-h urine collection sample.5,6 In
these patients, microscopic hematuria is mostly secondary to
micro- or macrolithiasis. However, with the increasing age of
prospective kidney donors, it is essential to rule out urothelial
malignancy by performing urine cytology, cystourethroscopy,
and renal imaging in those with persistent microscopic
hematuria. Renal ultrasound could be used to detect
structural pathology such as cysts, neoplasia, and tumors,
but its ability to detect small tumors is quite limited. Instead
for this reason, computed tomography with intravenous
Table 2 | Algorithm to investigate microscopic hematuria
in donors
Persistent Microscopic Hematuria
Two or more positive dipstick urine tests on separate occasions
over at least one-month period
Need to undergo 
Detailed family history for TBMN, Alport’s syndrome etc
Urine culture to rule out infection
24 hour urine collection to estimate protein, calcium, urate etc
Cytology to look for malignancy
Cystoscopy
Renal imaging:
CT-Renal angiogram to look for Nephrolithiasis, urothelial cancer
(or) and also to assess anatomy of renal vasculature 
Intravenous Pyelography
For those willing to undergo further evaluation
Renal Biopsy should be perfomed
If no urological cause found, then Counseling and option for deferring donation
Deferred donation
Further follow-up with PCP
Table 3 | Causes of persistent microscopic hematuria
(A) Glomerular bleeding (common causes, not associated with proteinuria or
casts)
1. TBMN
2. AS (early stage) or carrier state
3. IgAN
(B) Extraglomerular bleeding
1. Stone disease
2. Hemoglobinopathy (SS/SA hemoglobin)
2. Polycystic kidney disease
3. Benign prostatic hyperplasia (elderly donors)
4. Malignancy (bladder, kidney, prostate)
5. Arteriovenous malformations and fistulas
6. Schistosomiasis (in endemic areas)
7. Hypercalciuria, hyperuricosuria, etc.
AS, Alport’s syndrome; IgAN, IgA nephropathy; TBMN, thin basement membrane
nephropathy.
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contrast is recommended. Intravenous pyelography used to
be the test of choice but is not recommended because it
entails extensive exposure to contrast and is quite a lengthy
and inconvenient procedure.
Prospective kidney donors should be informed that the
presence of persistent, isolated, asymptomatic microscopic
hematuria generally precludes the continued possibility of
donation. Most donors drop their candidacy at this point and
a biopsy is often unnecessary, as the presumptive diagnosis is
usually quite clear and the overall long-term prognosis is
excellent. If the potential donor candidate remains deter-
mined to proceed with a workup then a biopsy is essentially
the next step in the workup. As mentioned earlier, kidney
biopsy, in most cases, is likely to reveal IgAN, TBMN, or AS.
Sobh et al.7 investigated 30 potential living related kidney
donors with isolated hematuria in Egypt. AS or a carrier state
was found to be the most common cause (25/30), followed by
isolated C3 deposits disease (3/30), IgAN (1/30), and IgM
nephropathy (1/30). They attributed this much higher pre-
valence of AS possibly to higher incidence of consanguineous
marriages in their population.
Better risk stratification through accurate diagnosis
Patients with AS and IgAN are not candidates for donation.
So it is very important to differentiate cases that resemble
TBMN but actually represent Alport’s carrier state or an early
stage of AS. Clinical features of these conditions overlap and
TBMN and AS share some histological abnormalities
(Table 4). TBMN is a common, mostly benign renal
condition and is transmitted in an autosomal-dominant
manner. So screening the first-degree relatives is helpful in
making this diagnosis in conjunction with histological
parameters. History of renal impairment among family
members is rare, contrary to what we observe in Alport’s
carrier families. Most individuals with TBMN have normal
renal function. Renal impairment with progression to end-
stage renal failure is rare.8 Proteinuria and hypertension are
the only known risk factors. Renal impairment in TBMN may
represent an aggressive variant or owing to coexistent renal
lesions (e.g. IgAN or focal segmental glomerulosclerosis) or
even misdiagnosed Alport’s.
In contrast to TBMN, AS is a less common but progressive
form of glomerular disease with associated sensory neural
hearing loss and ocular abnormalities. AS is a genetically
heterogeneous disease with X-linked recessive (85%), auto-
somal-recessive (15%), and autosomal-dominant (5%)
variants. Women with Alport’s carrier state carry a small
but significant risk (8–12% in one series by Dagher et al.9) of
renal failure. Electron microscopy and immunohistochem-
istry may help differentiating TBMN from AS. Electron
microscopy in AS typically shows GBM lamellation and
thickening, but these changes may be absent or patchy in
female carriers and in early disease. Analysis of type IV
collagen expression by immunostaining will show no staining
in most patients with Alport’s, discontinuous staining in
female carriers, and normal staining in TBMN.10 However, it
is important to note that in AS, staining for subtypes of type
IV collagen is not always abnormal. In fact, a normal
distribution of staining is seen in a significant minority of
cases. Among individuals with ongoing suspicion or incon-
clusive pattern, for absolute exclusion of asymptomatic
carrier state, molecular genetic testing would be extremely
helpful.11 However, genetic testing for AS is commercially
available only in very few centers and its interpretation could
be limited owing to the large number of potential mutations.
Implications for kidney donation
No patient with apparent TBMN should be considered as a
donor if there is a family history of progressive renal disease,
any evidence of extrarenal manifestation (i.e. sensorineural
hearing loss or conus lenticularis) or of the presence of GBM
lamellation. It is also generally accepted that TBMN patients
with risk factors for progressive disease such as hypertension,
proteinuria, or overt renal insufficiency should not be
accepted as donors. However, there still remains some
controversy regarding whether patients with TBMN with
isolated hematuria should be accepted as donors.12,13 It is
important to note, however, that it is even more controversial
to consider patients with heterozygous COL4A5 genetic
defect as live renal transplant donors. Although renal
donation with parents to their children (mother to son with
X-linked Alport’s and father to daughter with autosomal-
Table 4 | Distinguishing factors for the three common causes of glomerular bleeding
TBMN Female carriers of X-linked Alport’s IgAN
1. Prevalence Common Uncommon Common
2. Family history of hematuria Common Common Only in isolated cases
3. Family history of renal failure Uncommon Common Usually absent
4. Family history of deafness Uncommon Common Absent
5. Deafness at adulthood Rare o10% incidence Absent
6. Retinopathy and lenticonus Absent Rare Absent
7. GBM by EM Thinned Thinned with regions of lamellation Normal
8. Type IV collagen in GBM a3–a5 chains all present Normal a3–a5 chain distribution or
patchy loss
Normal
9. IgA staining Negative Negative Positive with C3 and IgG in mesangium
10. Genes affected COL4A3/COL4A4 COL4A5 6q22–23
EM, electron microscopy; GBM, glomerular basement membrane; Ig, immunoglobulin; IgAN, IgA nephropathy; TBMN, thin basement membrane nephropathy.
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recessive Alport’s) with AS has been reported with good
short-term outcome for donor and recipient, the actual long-
term risk remains unknown.12–14 However, again it has to be
emphasized that, at least in our opinion, any of these patients
with evidence of extrarenal manifestations, hypertension, or
proteinuria should be deferred from donation.
Isolated proteinuria in prospective donors
Isolated proteinuria is not an uncommon finding during
donor workup. Currently in most centers, individuals with
proteinuria of greater than 150 mg/day will be disqualified as
potential kidney donors. A persistent proteinuric state should
be differentiated from transient or orthostatic proteinuria.
Evaluation of patient with mild proteinuria should include
testing the urine on at least two other occasions. The urine
sediment should also be examined for other signs of
glomerular pathology such as hematuria, red cell casts, etc.
Persistent proteinuria can be evaluated with a 24-h urine
collection or a random total protein-to-creatinine ratio.
Renal imaging studies will help to rule out structural renal
pathology. In the Okinawa General Health maintenance
Association study,15 a strong graded relationship between
dipstick-positive proteinuria and ESRD in general population
was noted. However, the rate of ESRD was only less than 2%
in those with mild proteinuria during almost two decades of
follow-up. In an effort to increase live donor transplantation
rate, Karpinski et al.16 proposed slight relaxation of current
rigid criteria. They defined potentially acceptable proteinuria
as 150–300 mg/dl. By accepting living donors with mild
proteinuria or mild hypertension, they estimated that, a
modest 3% increase in transplantation rate could be achieved
in their waitlisted ESRD population. In our own practice,
patients with mild proteinuria (150–200 mg/24 h of protein-
uria) but who are normoalbuminuric (o30 mg albumin/g
creatinine for male and o35 mg albumin/g creatinine for
female subjects) may be acceptable as kidney donors as long
as there are no other risk factors (e.g. the presence of even
mild hypertension).
Although many follow-up studies of ideal donors reported
no significant increase in hypertension, proteinuria, or renal
impairment, some observed slight increase in these outcomes
compared to healthy siblings or age-matched controls. Based
on this, one should assume that the actual long-term risk for
these marginal donors would be higher, but at present actual
risk is not quantifiable. Individuals with this presentation are
likely to represent older individuals like parents of potential
recipients, with much higher motivation to donate for their
loved ones. At present there is no uniform agreement and the
acceptance of these marginal donors is variable between
different transplant centers.
CONCLUSION
Asymptomatic urinary abnormalities in the prospective
donor population need a thorough evaluation in order to
identify the underlying pathology. In addition, careful
assessment of the patient’s family history and a meticulous
screening of family members for urinary abnormalities is
important in screening for underlying kidney disease.
Because of limited long-term outcome data, the actual risk
of kidney donation in these individuals is currently unknown.
In the interim, a full explanation of possible outcomes after
kidney donation should be offered to the very motivated
donors. Each case has to be carefully assessed in the context
of the donor and recipient’s wishes and their medical
needs. Input may also be needed from an ethics committee.
Notwithstanding, a further understanding of the patho-
logic, molecular, and genetic features of these conditions
would be very helpful in stratifying those with least risk
of kidney donation. Similarly, in future, the long-term
follow-up and outcome studies in these ‘marginal donor
population’ would be invaluable in clarifying the above
uncertainties.
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